Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways

BACKGROUND: Regorafenib is an inhibitor of multiple kinases with aberrant expression and activity in neuroblastoma tumours that have potential roles in neuroblastoma pathogenesis. METHODS: We evaluated neuroblastoma cells treated with regorafenib for cell viability and confluence, and analysed treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Subramonian, Divya, Phanhthilath, Nikki, Rinehardt, Hannah, Flynn, Sean, Huo, Yuchen, Zhang, Jing, Messer, Karen, Mo, Qianxing, Huang, Shixia, Lesperance, Jacqueline, Zage, Peter E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434894/
https://www.ncbi.nlm.nih.gov/pubmed/32457362
http://dx.doi.org/10.1038/s41416-020-0905-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434894/
https://www.ncbi.nlm.nih.gov/pubmed/32457362
http://dx.doi.org/10.1038/s41416-020-0905-8

Ejemplares similares